Lenvatinib Mesylate Entèmedyè CAS 15568-85-1 Pite> 97.0% (HPLC) Faktori

Deskripsyon kout:

5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione

CAS: 15568-85-1

Pite:> 97.0% (HPLC)

Aparans: Powder jòn

Entèmedyè nan Lenvatinib Mesylate CAS 857890-39-2

Kontakte: Dr Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Voye imèl ba nou

Pwodwi detay

Pwodwi ki gen rapò

Tags pwodwi

Deskripsyon:

Ruifu Chimik Pwovizyon pou Lenvatinib Mesylate Entèmedyè ak Pite segondè
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4

Pwopriyete chimik:

Non Chimik	5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione
Sinonim	5-(Methoxymethylene) Asid Meldrum a;Cabozantinib enpurte 56;Lenvatinib enpurte 79
Nimewo CAS	15568-85-1
Nimewo CAT	RF-PI1967
Estati Stock	Nan Stock, Pwodiksyon Echèl Jiska Tòn
Fòmil molekilè	C8H10O5
Pwa molekilè	186.16
Pwen k ap fonn	132.0 ~ 134.0 ℃
Dansite	1.297±0.06 g/cm3
Mak	Ruifu Chimik

Espesifikasyon:

Atik	Espesifikasyon
Aparans	Poud jòn
Spectre 1H RMN	Ki konsistan avèk estrikti
Pite / Metòd analiz	>97.0% (HPLC)
Enpurte total	<3.00%
Tès Creole	Enterprise Standard
Itilizasyon	Entèmedyè nan Lenvatinib Mesylate (CAS: 857890-39-2)

Pake & Depo:

Pake: Boutèy, sak papye aliminyòm, 25kg / tanbou katon, oswa selon kondisyon kliyan an

Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè ak imidite

Avantaj:

FAQ:

Aplikasyon:

5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione (CAS:15568-85-1) se yon entèmedyè nan Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib se yon dwòg kansè tiwoyid devlope pa Eisai Corporation nan Japon (Kòd: E7080), ki fè pati inibitè a nan oral milti-reseptè tirozin kinaz (RTK) epi li ka anpeche aktivite a kinaz nan faktè a kwasans endothelial vaskilè (VEGF) Reseptè VEGFR1. FLT1), VEGFR2 (KDR), ak VEGFR3 (FLT4).Lenvatinib kapab tou anpeche patisipasyon lòt RTK nan anjyogenesis patolojik, kwasans timè, ak pwogresyon kansè eksepte pou fonksyon selilè nòmal yo ki gen ladan reseptè FGFR1, 2, 3, ak 4 fibroblast kwasans faktè (FGF);reseptè faktè kwasans ki sòti nan plakèt (PDGFR [alfa]), KIT, ak RET.[Endikasyon]: Lenvatinib se apwopriye pou tretman pasyan kansè tiwoyid nan repetisyon lokal oswa kalite metastaz, kalite pwogresivite ak yòd radyoaktif-refractory kalite différenciés.Nan dat 13 fevriye 2015, US FDA te apwouve Lenvatinib dwòg antikansè pou tretman kansè tiwoyid.Lenvatinib se yon inibitè anzim milti-sib, ki kapab anpeche VEGFR2 ak VEGFR3 (reseptè faktè kwasans endothelial vaskilè).Non komèsyal Lenvatinib se Lenvima.Nan dat 20 me 2015, Ajans Medikaman Ewopeyen an (EMA) te apwouve Lenvatinib pou tretman kansè tiwoyid pwogrese, lokalman avanse oswa metastatik diferansye (papilè, folikulèr, kalite Hurthle) kansè tiwoyid (DTC).Nan jijman an, tan siviv medyàn pou pasyan ki gen DTC radyoaktif yòd-refractory trete ak Lenvatinib te 18 mwa pandan ke valè a pou pasyan ki pran plasebo se sèlman 3 mwa.